ALPHA TAU ANNOUNCES FDA APPROVAL TO EXPAND ALPHA DART® U.S. RECURRENT GLIOBLASTOMA REGAIN TRIAL; NEW TRIAL DATA TO BE PRESENTED AT SNO 2026 ANNUAL MEETING

Reuters · 2d ago

Please log in to view news